Drug Treatment of Raynaud’s Phenomenon
Publisher
Springer New York
Reference105 articles.
1. Pope J. Raynaud’s phenomenon (primary). Clin Evid. 2003;9:1339–48.
2. Huisstede BM, Hoogvliet P, Paulis WD, van Middelkoop M, Hausman M, Coert JH, Koes BW. Effectiveness of interventions for secondary Raynaud’s phenomenon: a systematic review. Arch Phys Med Rehabil. 2011;92(7):1166–80. doi:
10.1016/j.apmr.2011.01.022.)
.
3. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–8. doi:
10.1136/ard.2008.096677
. PMID: 19147617.
4. Walker KM, Pope J, et al. Treatment of systemic sclerosis (SSc) including organ involvement: what to use when firstline treatment fails – a consensus of SSc experts. Semin Arthritis Rheum. 2012;42(1):42–55.
5. Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud’s phenomenon: a review. Semin Arthritis Rheum. 2012;41:599–603.